These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 29298274)

  • 1. Plasma apolipoprotein-B is an important risk factor for cardiovascular disease, and its assessment should be routine clinical practice.
    Trompet S; Packard CJ; Jukema JW
    Curr Opin Lipidol; 2018 Feb; 29(1):51-52. PubMed ID: 29298274
    [No Abstract]   [Full Text] [Related]  

  • 2. Introduction: Apolipoproteins and guidelines for prevention of cardiovascular disease.
    Faergeman O
    J Intern Med; 2006 May; 259(5):434-6. PubMed ID: 16629848
    [No Abstract]   [Full Text] [Related]  

  • 3. [The importance of A1 and B apoproteins as cardiovascular risk markers].
    Sánchez FM; Albo Castaño MI; Casallo Blanco S; Vizuete Calero A; Matías Salces Ld
    An Med Interna; 2008 Apr; 25(4):199-200. PubMed ID: 18604341
    [No Abstract]   [Full Text] [Related]  

  • 4. Another step forward in refining risk stratification: moving past low-density lipoprotein cholesterol.
    Milani RV; Lavie CJ
    J Am Coll Cardiol; 2011 Jul; 58(5):464-6. PubMed ID: 21777741
    [No Abstract]   [Full Text] [Related]  

  • 5. Apolipoproteins for cardiovascular risk assessment.
    Chang JG; Paulson CP; Smith RF
    Am Fam Physician; 2014 Apr; 89(8):Online. PubMed ID: 24784129
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical utility of low-density lipoprotein particles and apolipoprotein B in patients with cardiovascular risk.
    Ennis JL; Cromwell WC
    J Fam Pract; 2013 Jul; 62(7 Suppl):1-8. PubMed ID: 23957035
    [No Abstract]   [Full Text] [Related]  

  • 7. [The cholesterol contained in low-density lipoproteins or apolipoprotein B in the prediction of cardiovascular risk?].
    Vella Ramírez JC
    Rev Sanid Hig Publica (Madr); 1992; 66(5-6):251-5. PubMed ID: 1366222
    [No Abstract]   [Full Text] [Related]  

  • 8. Biomarkers of cardiovascular disease risk in women.
    Manson JE; Bassuk SS
    Metabolism; 2015 Mar; 64(3 Suppl 1):S33-9. PubMed ID: 25487190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular risk according to plasma apolipoprotein and lipid profiles in a Canadian First Nation.
    Riediger ND; Bruce SG; Young TK
    Chronic Dis Can; 2010 Dec; 31(1):33-8. PubMed ID: 21213617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic syndrome and carotid intima-media thickness in young adults: roles of apolipoprotein B, apolipoprotein A-I, C-reactive protein, and secretory phospholipase A2: the cardiovascular risk in young Finns study.
    Mattsson N; Magnussen CG; Rönnemaa T; Mallat Z; Benessiano J; Jula A; Taittonen L; Kähönen M; Juonala M; Viikari JS; Raitakari OT
    Arterioscler Thromb Vasc Biol; 2010 Sep; 30(9):1861-6. PubMed ID: 20539018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Plasma apolipoproteins: their role in cardiovascular diseases and usefulness of their blood concentration determination. Committee of the Study of Apolipoproteins, Italian Heart Foundation].
    Cardiologia; 1997 Feb; 42 Suppl 1():1-39. PubMed ID: 9147845
    [No Abstract]   [Full Text] [Related]  

  • 12. Is there a better marker of cardiovascular risk than LDL cholesterol? Apolipoproteins B and A-I--new risk factors and targets for therapy.
    Walldius G; Jungner I
    Nutr Metab Cardiovasc Dis; 2007 Oct; 17(8):565-71. PubMed ID: 17631989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apo B/apo A-I ratio and cardiovascular risk prediction.
    Lima LM; Carvalho Md; Sousa MO
    Arq Bras Cardiol; 2007 Jun; 88(6):e187-90. PubMed ID: 17664987
    [No Abstract]   [Full Text] [Related]  

  • 14. Low HDL cholesterol levels in type I Gaucher disease do not lead to an increased risk of cardiovascular disease.
    de Fost M; Langeveld M; Franssen R; Hutten BA; Groener JE; de Groot E; Mannens MM; Bikker H; Aerts JM; Kastelein JJ; Hollak CE
    Atherosclerosis; 2009 May; 204(1):267-72. PubMed ID: 18842264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apolipoprotein B versus non-high-density lipoprotein cholesterol: and the winner is..
    Sniderman AD
    Circulation; 2005 Nov; 112(22):3366-7. PubMed ID: 16316960
    [No Abstract]   [Full Text] [Related]  

  • 16. Enzyme-Linked Immunoassay-Based Quantitative Measurement of Apolipoprotein B (ApoB) in Dried Blood Spots, a Biomarker of Cardiovascular Disease Risk.
    Eick GN; Kowal P; Barrett T; Thiele EA; Snodgrass JJ
    Biodemography Soc Biol; 2017; 63(2):116-130. PubMed ID: 28521623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of future cardiovascular disease with an equation to estimate apolipoprotein B in patients with high cardiovascular risk: an analysis from the TNT and IDEAL study.
    Hwang YC; Ahn HY; Han KH; Park SW; Park CY
    Lipids Health Dis; 2017 Aug; 16(1):158. PubMed ID: 28830468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperlipidaemia and cardiovascular disease.
    Somers VK; Chappell DA
    Curr Opin Lipidol; 1996 Dec; 7(6):U193-201. PubMed ID: 9117133
    [No Abstract]   [Full Text] [Related]  

  • 19. Risks and benefits of replacing conventional plasma lipids with apolipoprotein measurement.
    Lippi G; Targher G; Guidi GC
    Acta Cardiol; 2009 Jun; 64(3):413-4; author reply 414. PubMed ID: 19593956
    [No Abstract]   [Full Text] [Related]  

  • 20. [Apolipoprotein B and LDL cholesterol: which parameter(s) should be included in the assessment of cardiovascular risk?].
    Bloch S; Couderc R
    Ann Biol Clin (Paris); 1998; 56(5):539-44. PubMed ID: 9769484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.